Document qaOX6wYVmkkDp14DN5banDY5M

CHEM EHSR 236 1B 3M Chemicals 651' 733 1958 12/09 '98 13:22 NO.461 01/01 3M Center S. Paul, MN 551*4-1000 612 733 i`ti rtj /lZ.> - oQJlSl December 9, 1998 Charles M. Auer, Director Chemical Control Division U.S. Environmental Protection Agency 401 M Street, S.W. Washington, D.C. 20460 Dear Mr. Auer. r*o => o CmO 0 - 5 "t? "Orn i -o o cn -- i r n *T? 2 m oo cn cr> Enclosed is our proposed agenda for the 3M meeting with EPA on Monday, December 14,1998 from 1:00 - 2:00 p.m. The purpose of the meeting is to give an overview of the issues surrounding the TSCA 8(e) filing in May, 1998 regarding the finding o f perfluorooctane sulfonate in blood samples from tire general population. The following individuals will be in attendance from 3M: Dr. Charles (Chuck) Reich Dr. W illiam (Bill) Weppner Mr. Daniel (Dan) Hakes Dr. Larry Zobel Group Vice President EHS&R Director Product Steward Specialist StafT Vice President And Medicai Director Chemical Markets Group Chemical Markets Group Chemical Markets Group 3M We have developed the following agenda :o fit within the scheduled meeting time o f one hour. Introduction and General Comments Product Overview Toxicology and Human Health Data Environmental Exposure Assessments/?rcduct Stewardship Discussion Dr. Charles Raich Dr. Weppner Dr. Zobel Dr. Wecpncr Ail By this meeting, we hope to begin working in partnership with the agency to review our testing activities and stewardship plans and to solicit agency input on our efforts. At the end of the hour we would like to develop a defined structure for follow up, including identifying a primary contact at . tire agency and scheduling working group sessions to review the science and our testing program in more detail. Please fee! free to contact me in advance o f the meeting if you have any questions or comments. Best regards. William A. Weppner, Ph.D. Director Environmental. Health, Safety & Regulatory Affairs Chemical Markets Group 3M Center. Bldg. 236-IB -I0 St. Paul. MN 55144 651/733-6374 /